Transient prehypertensive treatment in spontaneously hypertensive rats: A comparison of losartan and amlodipine regarding long-term blood pressure, cardiac and renal protection

Peng,Feng; Lin,Jinxiu; Lin,Liming; Tang,Hong

doi:10.3892/ijmm.2012.1153

Transient prehypertensive treatment in spontaneously hypertensive rats: A comparison of losartan and amlodipine regarding long-term blood pressure, cardiac and renal protection

Authors:
- Feng Peng
- Jinxiu Lin
- Liming Lin
- Hong Tang
View Affiliations

Affiliations: The First Clinical Medical College of Fujian Medical University, Fuzhou 350005, P.R. China
Published online on: October 9, 2012 https://doi.org/10.3892/ijmm.2012.1153
Pages: 1376-1386

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to compare the effectiveness of transient prehypertensive treatment with losartan compared with amlodipine in spontaneously hypertensive rats (SHRs) on long-term blood pressure (BP), cardiac and renal protection. SHRs were prehypertensively treated with losartan, amlodipine or saline. Rats were followed up until 46 weeks of age. The left ventricular (LV) geometry and function were assessed by echocardiography. Angiotensin II (Ang II) and aldosterone (Aldo) were measured by radioimmunoassay. Ang II type 1 (AT1R) and type 2 (AT2R) receptor protein expression was determined by western blotting. The systolic blood pressure (SBP) in losartan-treated SHRs (SHR-Los) was persistently reduced until 46 weeks of age, but returned to untreated SHR levels in amlodipine-treated SHRs (SHR-Aml) from 30 weeks onwards. Compared to untreated SHRs, the albuminuria excretion in SHR-Los at week 46 was markedly decreased, the plasma, myocardium and renal tissue Ang II and Aldo levels in SHR-Los at week 46 were markedly decreased; AT1R and TGF-β1 protein expression was downregulated and AT2R protein was upregulated. Compared to untreated SHRs, the left ventricular mass index (LVMI) and collagen volume fraction (CVF) in SHR-Los were markedly decreased until week 46, and the left ventricular ejection fraction (LVEF) and cardiac brain natriuretic peptide mRNA expression were improved, whereas similar LVMI and elevated CVF were observed in SHR-Aml, and the LVEF decreased significantly below that of untreated SHRs at week 46, with cardiac BNP mRNA expression increasing slightly. Prehypertensive treatment with losartan was more effective than amlodipine on delaying long-term BP increase and ameliorating cardiac, renal structure and function, which may be related to the permanent attenuation of the circulating and local renin-angiotensin systems.

View Figures

View References

1.	RS VasanMG LarsonEP LeipWB KannelD LevyAssessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort studyLancet35816821686200110.1016/S0140-6736(01)06710-111728544
2.	J HsiaKL MargolisCB EatonPrehypertension and cardiovascular disease risk in the Women’s Health InitiativeCirculation1158558602007
3.	S KnechtH WerschingH LohmannHigh-normal blood pressure is associated with poor cognitive performanceHypertension51663668200810.1161/HYPERTENSIONAHA.107.10557718250360
4.	DR MullicanC LorenzoSM HaffnerIs prehypertension a risk factor for the development of type 2 diabetes?Diabetes Care3218701872200910.2337/dc09-032819628813
5.	T NinomiyaM KuboY DoiPrehypertension increases the risk for renal arteriosclerosis in autopsies: the Hisayama StudyJ Am Soc Nephrol1821352142200710.1681/ASN.200701006717582160
6.	AV ChobanianGL BakrisHR BlackThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA28925602572200310.1001/jama.289.19.2560
7.	S JuliusSD NesbittBM EganFeasibility of treating prehypertension with an angiotensin-receptor blockerN Engl J Med35416851697200610.1056/NEJMoa06083816537662
8.	S LudersJ SchraderJ BergerThe PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension LeagueJ Hypertens2614871496200810.1097/HJH.0b013e3282ff8864
9.	SB HarrapWM Van der MerweSA GriffinF MacphersonAF LeverBrief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-termHypertension16603614199010.1161/01.HYP.16.6.603
10.	M BaumannBJ JanssenJJ HermansTransient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced ageJ Hypertens25207215200710.1097/HJH.0b013e3280102bff
11.	M BaumannJJ HermansBJ JanssenTransient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damageJ Hypertens2525042511200710.1097/HJH.0b013e3282ef84f8
12.	D TomassoniM SabbatiniF AmentaEffect of different dihydropyridine-type Ca²⁺ antagonists on left ventricle hypertrophy and coronary changes in spontaneously hypertensive ratsJ Cardiovasc Pharmacol41544552200312658055
13.	M WatanabeH KawaguchiH OnozukaChronic effects of enalapril and amlodipine on cardiac remodeling in cardiomyopathic hamster heartsJ Cardiovasc Pharmacol32248259199810.1097/00005344-199808000-000129700987
14.	RE WiddopXC LiA simple versatile method for measuring tail cuff systolic blood pressure in conscious ratsClin Sci (Lond)9319119419979337632
15.	RM LangM BierigRB DevereuxRecommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of CardiologyJ Am Soc Echocardiogr1814401463200516376782
16.	J FloegeB HackmannV KliemAge-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: a podocyte diseaseKidney Int51230243199710.1038/ki.1997.288995738
17.	Y XuD KumarJR DyckAT(1) and AT(2) receptor expression and blockade after acute ischemia-reperfusion in isolated working rat heartsAm J Physiol Heart Circ Physiol282H1206H1215200210.1152/ajpheart.00839.200011893553
18.	KL ChristensenLT JespersenMJ MulvanyDevelopment of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structureJ Hypertens78390198910.1097/00004872-198902000-000022522478
19.	K IshiguroH SasamuraY SakamakiH ItohT SarutaDevelopmental activity of the renin-angiotensin system during the ‘critical period’ modulates later L-NAME-induced hypertension and renal injuryHypertens Res3063752007
20.	H NakayaH SasamuraM MifunePrepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive ratsNephron91710718200210.1159/00006503512138277
21.	H SasamuraK HayashiK IshiguroH NakayaT SarutaH ItohPrevention and regression of hypertension: role of renal microvascular protectionHypertens Res32658664200910.1038/hr.2009.8519521419
22.	AK KeatonCR WhiteKH BerecekCaptopril treatment and its withdrawal prevents impairment of endothelium-dependent responses in the spontaneously hypertensive ratClin Exp Hypertens20847866199810.3109/106419698090532519817606
23.	L ZhangDG EdwardsKH BerecekEffects of early captopril treatment and its removal on plasma angiotensin converting enzyme (ACE) activity and arginine vasopressin in hypertensive rats (SHR) and normotensive rats (WKY)Clin Exp Hypertens18201226199610.3109/106419696090817658869001
24.	JN WuKH BerecekPrevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captoprilHypertension22139146199310.1161/01.HYP.22.2.1398340149
25.	M BaumannBJ JanssenJJ Rob HermansR BartholomeJF SmitsHA Struijker BoudierRenal medullary effects of transient prehypertensive treatment in young spontaneously hypertensive ratsActa Physiol (Oxf)196231237200910.1111/j.1748-1716.2008.01916.x18983459
26.	MA SevillaF VocesR CarronAmlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawalLife Sci75881891200410.1016/j.lfs.2004.04.00415183079
27.	K TakemoriH IshidaH ItoContinuous inhibition of the renin-angiotensin system and protection from hypertensive end-organ damage by brief treatment with angiotensin II type 1 receptor blocker in stroke-prone spontaneously hypertensive ratsLife Sci7722332245200510.1016/j.lfs.2004.12.048
28.	M BaderRole of the local renin-angiotensin system in cardiac damage: a minireview focussing on transgenic animal modelsJ Mol Cell Cardiol3414551462200210.1006/jmcc.2002.207712431444
29.	K MizunoM TaniS HashimotoEffects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive ratsLife Sci51367374199210.1016/0024-3205(92)90589-H
30.	MA AdamsA BobikPI KornerDifferential development of vascular and cardiac hypertrophy in genetic hypertension. Relation to sympathetic functionHypertension14191202198910.1161/01.HYP.14.2.1912527201
31.	R BurgesD MoiseyUnique pharmacologic properties of amlodipineAm J Cardiol732A9A199410.1016/0002-9149(94)90268-2
32.	T NaitoLJ MaH YangAngiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosisAm J Physiol Renal Physiol298F683F691201010.1152/ajprenal.00503.200920042458
33.	K SkovH EiskjaerHE HansenJK MadsenS KvistMJ MulvanyTreatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blockerHypertension508995200710.1161/HYPERTENSIONAHA.107.08953217485597